Brii Biosciences Limited

SHSC:2137 Stock Report

Market Cap: HK$904.7m

Brii Biosciences Management

Management criteria checks 3/4

Brii Biosciences' CEO is Zhi Hong, appointed in Jan 2018, has a tenure of 6.17 years. total yearly compensation is CN¥14.31M, comprised of 47.5% salary and 52.5% bonuses, including company stock and options. directly owns 4.46% of the company’s shares, worth HK$40.33M. The average tenure of the management team and the board of directors is 2.2 years and 3.6 years respectively.

Key information

Zhi Hong

Chief executive officer

CN¥14.3m

Total compensation

CEO salary percentage47.5%
CEO tenure6.2yrs
CEO ownership4.5%
Management average tenure2.2yrs
Board average tenure3.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Zhi Hong's remuneration changed compared to Brii Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2023n/an/a

-CN¥327m

Mar 31 2023n/an/a

-CN¥405m

Dec 31 2022CN¥14mCN¥7m

-CN¥484m

Sep 30 2022n/an/a

-CN¥1b

Jun 30 2022n/an/a

-CN¥2b

Mar 31 2022n/an/a

-CN¥3b

Dec 31 2021CN¥65mCN¥37m

-CN¥4b

Sep 30 2021n/an/a

-CN¥4b

Jun 30 2021n/an/a

-CN¥4b

Mar 31 2021n/an/a

-CN¥3b

Dec 31 2020CN¥22mCN¥5m

-CN¥1b

Dec 31 2019CN¥20mCN¥4m

-CN¥521m

Compensation vs Market: Zhi's total compensation ($USD1.99M) is above average for companies of similar size in the Hong Kong market ($USD237.73K).

Compensation vs Earnings: Zhi's compensation has been consistent with company performance over the past year.

CEO

Zhi Hong (59 yo)

6.2yrs

Tenure

CN¥14,305,000

Compensation

Dr. Zhi Hong, PhD, co-founded Brii Biosciences Limited in 2018 and serves as its Executive Chairman of the Board, Chief Executive Officer & Executive Director since 2018. Prior to starting Brii Bio, Dr. Ho...

Leadership Team

NamePositionTenureCompensationOwnership
Zhi Hong
Co-founder6.2yrsCN¥14.31m4.46%
HK$ 40.3m
Ankang Li
Chief Financial & Strategy Officer2.9yrsCN¥11.32m0.17%
HK$ 1.5m
Eleanor de Groot
Chief Technology Officer1.6yrsno datano data
Brian Johns
Chief Scientific Officerless than a yearno datano data
Sarah Qiu
Associate Director of Investor Relationsno datano datano data
Karen Del Barrio Neuendorff
Chief People Officer & Head of Human Resources2.2yrsno datano data
Coy Stout
Head of Patient Advocacy2.5yrsno datano data
Lianhong Xu
Head of Discoveryno datano datano data
Qing Zhu
Head of China Research & Development3.7yrsno datano data
David Margolis
Chief Medical Officerno datano datano data
Susannah Cantrell
Chief Business Officer1.7yrsno datano data
Aleksandar Skuban
Head of Central Nervous System Diseases Therapy Area Head1.6yrsno datano data

2.2yrs

Average Tenure

54yo

Average Age

Experienced Management: 2137's management team is considered experienced (2.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Zhi Hong
Co-founder6.2yrsCN¥14.31m4.46%
HK$ 40.3m
Ankang Li
Chief Financial & Strategy Officer1.5yrsCN¥11.32m0.17%
HK$ 1.5m
Robert Taylor Nelsen
Non-Executive Director5.8yrsno datano data
Yiu Wa Tsui
Independent Non-executive Directorno dataCN¥922.00k0.010%
HK$ 90.6k
Gregg Alton
Independent Non-executive Directorno dataCN¥922.00k0.010%
HK$ 90.6k
Taiyin Yang
Independent Non-Executive Director1.5yrsCN¥308.00k0.015%
HK$ 135.2k
Martin J. Murphy
Independent Non-executive Directorno dataCN¥922.00k0.010%
HK$ 90.6k
Hui Tang
Independent Non-executive Directorno dataCN¥922.00k0.010%
HK$ 90.6k

3.6yrs

Average Tenure

62yo

Average Age

Experienced Board: 2137's board of directors are considered experienced (3.6 years average tenure).